HIT Consultant January 14, 2025
What You Should Know:
– Medtronic (NYSE:MDT), a global leader in healthcare technology, announced it has received CE Mark approval for its groundbreaking BrainSense™ Adaptive deep brain stimulation (aDBS) technology in the European Union and the United Kingdom.
– The CE approval marks a significant advancement in personalized Parkinson’s disease treatment, offering patients in Europe access to a more responsive and tailored therapy.
BrainSense™ aDBS: A New Era of Personalized Parkinson’s Treatment
For three decades, deep brain stimulation (DBS) has been a valuable tool for managing Parkinson’s disease symptoms. This technology involves implanting a device that sends electrical signals to specific brain regions to disrupt abnormal nerve signals that cause tremors and other movement difficulties.
BrainSense™ aDBS takes...
Today's Sponsors
Today's Sponsor